Xiamen Jindawei Group Co., Ltd. announced that the company and its subsidiaries, Inner Mongolia Jindawei Pharmaceutical Co., Ltd. and Jindawei Biotechnology (Jiangsu) Co., Ltd., recently received one invention patent certificate issued by the National Intellectual Property Administration. The patent is titled "A Separation and Purification Method for Pyrroloquinoline Quinone Disodium Salt," with patent number ZL202510024727.1, and the grant announcement date is July 17, 2026. The patent belongs to the field of compound purification technology and can effectively improve the purity of pyrroloquinoline quinone disodium salt. The company stated that the acquisition of this patent will not have a significant impact on production and operations, but it is conducive to technological innovation and enhances core competitiveness.
Xiamen Kingdomway Group CoObtained a new invention patent for a separation and purification method, enhancing technological innovation and core competitiveness.
Subsidiary received the patent, which improves purification technology and supports innovation.